Combination immunotherapy improves survival in mouse models of mesothelioma
Mass. The general team reports promising preclinical results against uniformly fatal tumor
April 2, 2018
Massachusetts General Hospital
Investigators have found that combined treatment with two cancer immunotherapy drugs — one a novel immune modulator and one that focuses and activates the anti-tumor immune response — significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.